Project
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First Line chemotherapy (DeLLphi-304)
Ongoing - recruitment active · 2023 until 2025
Früh Martin, Hutter Franziska, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2023
End Date
2025
Financing
Industry
Phase
III
Labels
lung cancer